Browsing by Author "Ding, Yi"

Now showing items 1-4 of 4

    • Distinct Receptor Tyrosine Kinase Subsets Mediate Anti-HER2 Drug Resistance in Breast Cancer. 

      Alexander, Peter B; Chen, Rui; Gong, Chang; Yuan, Lifeng; Jasper, Jeff S; Ding, Yi; Markowitz, Geoffrey J; ... (12 authors) (J Biol Chem, 2017-01-13)
      Targeted inhibitors of the human epidermal growth factor receptor 2 (HER2), such as trastuzumab and lapatinib, are among the first examples of molecularly targeted cancer therapy and have proven largely effective for the ...

    • Metabolic vulnerability in HER2-positive Breast Cancer 

      Ding, Yi (2018)
      The human epidermal growth factor receptor 2, or HER2, is overexpressed in 20-30% breast cancer patients and is associated with aggressive disease. Therapies targeting HER2, including monoclonal antibodies (trastuzumab and ...

    • Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers. 

      Ding, Yi; Gong, Chang; Huang, De; Chen, Rui; Sui, Pinpin; Lin, Kevin H; Liang, Gehao; ... (17 authors) (Nature communications, 2018-10)
      Intrinsic resistance to anti-HER2 therapy in breast cancer remains an obstacle in the clinic, limiting its efficacy. However, the biological basis for intrinsic resistance is poorly understood. Here we performed ...

    • UHRF1 is required for basal stem cell proliferation in response to airway injury. 

      Xiang, Handan; Yuan, Lifeng; Gao, Xia; Alexander, Peter B; Lopez, Omar; Lau, Calvin; Ding, Yi; ... (16 authors) (Cell Discov, 2017)
      Cellular senescence is a cell fate characterized by an irreversible cell cycle arrest, but the molecular mechanism underlying this senescence hallmark remains poorly understood. Through an unbiased search for novel senescence ...